YOLFTbeta
Denali Therapeutics Inc

Denali Therapeutics Inc

DNLI · NASDAQ · Healthcare / Biotechnology

18.74USD-0.15 (-0.79%)

Price History

Full chart

Market Stats

Previous Close18.89
Open18.77
Day Range18.34 – 19.01
52-Week Range13.75 – 27.30
Volume795.67K
Market Cap3.26B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.84
Dividend Yield0.00%
Beta1.00
50-Day Avg23.19
200-Day Avg20.99

About

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Ryan J. Watts Ph.D.
  • Employees503
  • Headquarters161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080, USA
  • Websitehttps://www.denalitherapeutics.com

Leadership

  • Dr. Ryan J. Watts Ph.D.Co-Founder, President, CEO & Director · b. 1976
  • Dr. Alexander O. Schuth M.D., Ph.D.Co-Founder, CFO, COO & Secretary · b. 1973
  • Dr. Dana AndersenChief Technical and Manufacturing Officer
  • Mr. Joe Lewcock Ph.D.Chief Scientific Officer
  • Mr. Chris Walsh J.D.General Counsel
  • Ms. Cindy DunkleChief People Officer
  • Ms. Katie Peng M.B.A.Chief Commercial Officer · b. 1971
  • Mr. Peter Chin M.D.Acting Chief Medical Officer & Head of Development · b. 1968

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000129.16M26.68M335.66M48.66M108.46M330.53M00
Growth (%)-----79.34%+1158.19%-85.50%+122.90%+204.74%-100.00%-
Cost of Revenue121.00K1.47M74.46M143.18M193.38M212.62M5.61M7.03M16.73M7.79M11.18M
Gross Profit-121.00K-1.47M-74.46M129.16M26.68M335.66M48.66M108.46M330.53M-7.79M-11.18M
Gross Margin---100.00%100.00%100.00%100.00%100.00%100.00%--
Operating Expense16.56M85.96M15.68M175.53M239.86M272.94M344.41M449.21M527.23M479.55M544.16M
Operating Income-16.68M-87.43M-90.14M-46.37M-213.18M62.72M-295.75M-340.74M-196.70M-487.34M-555.34M
Operating Margin----35.90%-799.10%18.69%-607.78%-314.16%-59.51%--
EBITDA-15.06M-85.96M-87.06M-38.96M-205.19M71.25M-287.16M-315.59M-128.47M-492.89M-497.63M
EBITDA Margin----30.16%-769.15%21.23%-590.12%-290.96%-38.87%--
Net Income-16.79M-86.65M-88.19M-36.24M-197.61M71.14M-290.58M-325.99M-145.22M-422.77M-512.54M
Net Income Margin----28.06%-740.74%21.19%-597.15%-300.56%-43.94%--
R&D11.57M75.70M74.46M143.18M193.38M212.62M265.35M358.73M423.88M396.44M418.78M
R&D as % of Total Revenue---110.86%724.87%63.34%545.31%330.74%128.24%--
Interest Expense109.00K01.96M1.96M15.22M17.77M13.19M14.77M---
Interest Expense % of Total Revenue---1.51%57.05%5.29%27.10%13.62%---

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets36.68M271.07M486.72M661.98M553.23M1.60B1.40B1.46B1.15B1.37B1.14B
Total Liabilities52.32M16.55M20.93M115.14M158.34M453.75M441.87M417.81M122.96M144.50M131.09M
Total Equity-15.63M254.52M465.80M546.85M394.89M1.15B962.29M1.04B1.03B1.23B1.01B
Cash30.74M39.85M218.38M77.12M79.45M507.14M293.48M218.04M127.11M174.96M205.33M
Total Debt----72.53M68.86M64.01M60.35M52.24M48.71M36.76M
Net Debt-30.74M-39.85M-218.38M-77.12M-6.92M-438.28M-229.47M-157.69M-74.86M-126.25M-168.57M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-15.05M-72.36M-76.64M50.12M-151.58M416.15M-211.39M-244.72M-357.99M-347.69M-412.60M
Investing Cash Flow-3.06M-219.00M-41.17M-287.42M147.71M-623.21M-21.63M-141.39M249.31M-88.76M255.28M
Financing Cash Flow48.85M300.48M296.32M97.02M6.19M634.75M19.35M310.67M17.82M484.30M189.22M
Capital Expenditure3.06M6.13M2.88M3.39M17.92M3.10M8.50M17.83M12.94M15.91M9.50M
Free Cash Flow-18.11M-78.49M-79.51M46.72M-169.50M413.06M-219.89M-262.55M-370.93M-363.61M-422.10M
FCF to OCF120.34%108.48%103.75%93.23%111.82%99.26%104.02%107.29%103.61%104.58%102.30%

Earnings

Report DateMay 4, 2017Dec 8, 2017Mar 19, 2018May 11, 2018Aug 9, 2018Nov 8, 2018Mar 12, 2019May 8, 2019Aug 6, 2019Nov 6, 2019Feb 27, 2020May 7, 2020Aug 7, 2020Nov 5, 2020Feb 25, 2021May 3, 2021Aug 4, 2021Nov 4, 2021Feb 28, 2022May 5, 2022Aug 8, 2022Nov 3, 2022Feb 27, 2023May 8, 2023Aug 8, 2023Nov 7, 2023Feb 27, 2024May 7, 2024Aug 1, 2024Nov 6, 2024Feb 25, 2025May 6, 2025Aug 11, 2025Nov 6, 2025Feb 26, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate0.000.00-0.200.30-0.22-0.29-0.11-0.44-0.46-0.55-0.58-0.57-0.612.20-0.60-0.34-0.36-0.38-0.41-0.45-0.55-0.79-0.79-0.70-0.63-0.79-0.80-0.66-0.69-0.63-0.85-0.70-0.74-0.76-0.75-0.71-0.72-0.67
EPS Actual-2.36-0.53-0.74-0.26-0.59-0.380.79-0.41-0.61-0.48-0.56-0.55-0.56-0.541.91-0.58-0.50-0.69-0.62-0.53-0.48-0.84-0.75-0.801.30-0.72-0.86-0.78-0.59-0.63-0.67-0.78-0.72-0.74-0.73-0.69-0.68-
Surprise---270.00%-186.67%-168.18%-31.03%818.18%6.82%-32.61%12.73%3.45%3.51%8.20%-124.55%418.33%-70.59%-38.89%-81.58%-51.22%-17.78%12.73%-6.33%5.06%-14.29%306.35%8.86%-7.50%-18.18%14.49%0.00%20.79%-11.43%2.70%2.63%2.67%2.82%5.56%-
Timing-Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap3.26B
Enterprise Value2.59B
Trailing P/E0.00
Forward P/E0.00
Price / Sales904.35
Price / Book3.92
EPS-2.84
Book Value5.23
Revenue (TTM)3.60M
Gross Profit (TTM)-397.21M
EBITDA-526.06M
Profit Margin0.00%
Operating Margin-3601.30%
Return on Equity-54.93%
Return on Assets-29.15%
Shares Outstanding159.85M
Shares Float155.10M
Beta1.00
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 19 analystsTarget 36.06
  • Strong Buy
    15
  • Buy
    4

Ownership Breakdown

Institutions
101.40%
Insiders
9.08%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    13.03M8.15%
  • Baillie Gifford & Co Limited.
    11.96M7.48%
  • T. Rowe Price Investment Management,Inc.
    8.52M5.33%
  • Temasek Holdings Ltd.
    7.01M4.39%
  • State Street Corp
    6.27M3.92%
  • Vanguard Capital Management, LLC
    6.15M3.85%
  • Vanguard Portfolio Management, LLC
    6.12M3.83%
  • FMR Inc
    4.58M2.86%
  • UBS Asset Mgmt Americas Inc
    4.43M2.77%
  • The Goldman Sachs Group Inc
    4.41M2.76%
  • Baker Bros Advisors LP
    3.73M2.33%
  • Geode Capital Management, LLC
    3.73M2.33%
  • Holocene Advisors, LP
    3.20M2.00%

Top Fund Holders

  • Scottish Mortgage Ord
    7.04M4.41%
  • T. Rowe Price Capital Appreciation
    6.19M3.87%
  • Vanguard MStar Total Stk Mkt Idx Invest
    4.30M2.69%
  • iShares Russell 2000 ETF
    3.77M2.36%
  • State Street® SPDR® S&P® Biotech ETF
    3.66M2.29%
  • Vanguard Small Cap Index
    3.10M1.94%
  • Vanguard US Growth Investor
    3.04M1.90%